About
Taking Precision Oncology to New Heights
Taking Precision Oncology to New Heights
Our mission is to accelerate scientific and medical breakthroughs and deliver well-tolerated medicines with greater efficacy and safety to people with the deadliest cancers.
We uncover novel approaches targeting the RAS signaling pathway so that we can translate findings into clinical applications near term.
With a trusted team of world-leading RAS cancer biologists, expert medicinal chemists, and proven drug developers, our collaborative ecosystem creates novel RAS-targeted small molecules to maximize patient benefit.
Professor of Tumor Biology and Cancer Research at UC San Francisco and Advisor to the National Cancer Institute’s RAS Initiative at Frederick National Laboratory for Cancer Research
Chairman
Founder & Chief Executive Officer at BridgeBio Pharma
Director
Managing Director at Cormorant Asset Management
Director
Partner, Head of Corporate Development at Omega Funds
Director